Daiwa upgraded AbbVie (ABBV) to Outperform from Neutral with a $214 price target
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- AbbVie’s Promising Phase 3 Study on Atogepant for Menstrual Migraine Prevention
- AbbVie’s Ubrogepant Study: A New Hope for Menstrual Migraine Relief
- AbbVie and Genmab’s Promising Update on B-Cell Lymphoma Treatment Study
- AbbVie and Genmab’s Promising Phase 3 Study for DLBCL Treatment
- Pfizer and AbbVie Collaborate on Promising Pediatric Antibiotic Study